NCT03292861
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
Enrolling by Invitation
PHASE2Ages 18–70InterventionalTreatmentCedars-Sinai Medical CenterInvestigator-initiated
~60 participants
Updated 2026-01-14 on ClinicalTrials.gov
What's tested:ThymoglobulinMycophenolate MofetilTacrolimusSirolimusCorticosteroids
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants With Composite Efficacy Failure at 12 Months
Measured over 12 Months
Conditions
Where it's being run
2 sites across 1 statesCalifornia2
Study leadership
- Jon Kobashigawa, MD · PRINCIPAL_INVESTIGATOR · Director
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Percentage of Participants With Composite Efficacy Failure at 12 Months12 Months
Composite efficacy failure is defined as development of de novo donor specific antibodies (measured by standardized alloantibody testing by Luminex and control sera, characterizing kinetics, specificities and relative binding strength) and ischemia on endomyocardial biopsy (characterized on biopsy by myocyte necrosis and/or regions of myocyte dropout) at 12 months post-transplant.